|
US2788341A
(en)
|
1953-03-06 |
1957-04-09 |
Ciba Pharm Prod Inc |
Process for the manufacture of aminoacyl compounds
|
|
US3624097A
(en)
|
1969-07-22 |
1971-11-30 |
Warner Lambert Co |
N-pyridine 5-aminooxazoles
|
|
US4109496A
(en)
|
1977-12-20 |
1978-08-29 |
Norris Industries |
Trapped key mechanism
|
|
FR2568880B1
(fr)
|
1984-08-07 |
1986-12-12 |
Synthelabo |
Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique
|
|
US4868103A
(en)
|
1986-02-19 |
1989-09-19 |
Enzo Biochem, Inc. |
Analyte detection by means of energy transfer
|
|
US5080891A
(en)
|
1987-08-03 |
1992-01-14 |
Ddi Pharmaceuticals, Inc. |
Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
|
AU643140B2
(en)
|
1991-05-31 |
1993-11-04 |
Sumitomo Pharmaceuticals Company, Limited |
Leukotriene B4 antagonist
|
|
EP0552108B1
(en)
|
1992-01-17 |
1999-11-10 |
Lakowicz, Joseph R. |
Energy transfer phase-modulation fluoro-immunoassay
|
|
WO1994010300A1
(en)
|
1992-10-30 |
1994-05-11 |
The General Hospital Corporation |
Interaction trap system for isolating novel proteins
|
|
US5656465A
(en)
|
1994-05-04 |
1997-08-12 |
Therion Biologics Corporation |
Methods of in vivo gene delivery
|
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
|
US5677158A
(en)
|
1995-06-07 |
1997-10-14 |
Research Foundation Of State University Of New York |
In vitro packaging of adeno-associated virus DNA
|
|
US5801030A
(en)
|
1995-09-01 |
1998-09-01 |
Genvec, Inc. |
Methods and vectors for site-specific recombination
|
|
US6180612B1
(en)
|
1997-10-31 |
2001-01-30 |
The University Of Virginia Patent Foundation |
Methods and compositions for targeting DNA metabolic processes using aminoglycoside derivatives
|
|
US6683058B1
(en)
|
1998-04-15 |
2004-01-27 |
Regents Of The University Of California |
Methods for therapy of neurodegenerative disease of the brain
|
|
WO1999061066A2
(en)
|
1998-05-27 |
1999-12-02 |
Avigen, Inc. |
Convection-enhanced delivery of aav vectors
|
|
JP2000095767A
(ja)
|
1998-09-28 |
2000-04-04 |
Takeda Chem Ind Ltd |
性腺刺激ホルモン放出ホルモン拮抗剤
|
|
WO2000024392A1
(en)
|
1998-10-26 |
2000-05-04 |
Sumitomo Pharmaceuticals Company, Limited |
β-AMYLOID FORMATION INHIBITORS
|
|
WO2000059905A1
(en)
|
1999-04-02 |
2000-10-12 |
Neurogen Corporation |
ARYL AND HETEROARYL FUSED AMINOALKYL-IMIDAZOLE DERIVATIVES: SELECTIVE MODULATORS OF GABAa RECEPTORS
|
|
CA2369553A1
(en)
|
1999-04-02 |
2000-10-12 |
Raymond F. Horvath |
N-benzimidazolylmethyl and n-indolylmethyl-benzamides and their use as crf modulators
|
|
WO2001059094A2
(en)
|
2000-02-11 |
2001-08-16 |
The Salk Institute For Biological Studies |
Method of regulating transcription in a cell by altering remodeling of cromatin
|
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
KR20030032922A
(ko)
|
2000-02-24 |
2003-04-26 |
싸이트 테라피스 인코포레이티드 |
세포의 동시 자극 및 농축
|
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US20020037281A1
(en)
|
2000-05-26 |
2002-03-28 |
Davidson Beverly L. |
Methods of transducing neural cells using lentivirus vectors
|
|
US6716622B2
(en)
|
2000-07-18 |
2004-04-06 |
Uab Research Foundation |
Tissue-specific self-inactivating gene therapy vector
|
|
US20030027335A1
(en)
|
2000-09-07 |
2003-02-06 |
Ruley H. Earl |
Genome engineering by cell-permeable DNA site-specific recombinases
|
|
US6562576B2
(en)
|
2001-01-04 |
2003-05-13 |
Myriad Genetics, Inc. |
Yeast two-hybrid system and use thereof
|
|
JP2003033179A
(ja)
|
2001-07-05 |
2003-02-04 |
Asahi Kasei Corp |
可逆的遺伝子導入ベクター
|
|
JP2003077651A
(ja)
|
2001-08-30 |
2003-03-14 |
Sharp Corp |
有機エレクトロルミネッセンス素子の製造方法
|
|
US7132438B2
(en)
|
2001-10-09 |
2006-11-07 |
Amgen Inc. |
Benzimidazole derivatives
|
|
US20050079512A1
(en)
|
2003-02-26 |
2005-04-14 |
Emerson Beverly M. |
Methods of modulating gene expression
|
|
US20040216178A1
(en)
|
2003-03-03 |
2004-10-28 |
Jones Stephen N |
Regulation of mdm2 function
|
|
WO2005007877A2
(en)
|
2003-07-18 |
2005-01-27 |
University Of Massachusetts |
Regulatable promoters for synthesis of small hairpin rna
|
|
BRPI0415563A
(pt)
|
2003-10-20 |
2007-01-02 |
Nsgene As |
método para o tratamento do mal de parkinson, uso de um vetor viral, vetor de expressão viral, composição farmacêutica, célula hospedeira isolada, linhagem de células de empacotamento, mamìfero não humano quimérico, dispositivo de cultura celular implantável, cápsula biocompatìvel, método para tratamento de uma doença do sistema nervoso, célula de mamìfero, e, método para produzir neurturin ou um seu equivalente funcional
|
|
US20060058255A1
(en)
|
2004-03-01 |
2006-03-16 |
Jianzhu Chen |
RNAi-based therapeutics for allergic rhinitis and asthma
|
|
WO2005112620A2
(en)
|
2004-05-18 |
2005-12-01 |
Massachusetts Institute Of Technology |
A cre-lox based method for conditional rna interference
|
|
AU2005261487A1
(en)
|
2004-07-12 |
2006-01-19 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Amide derivatives as inhibitors of histone deacetylase
|
|
RU2007121864A
(ru)
|
2004-11-11 |
2008-12-20 |
Феррер Интернасионал |
ИМИДАЗО[1,2-a]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ (ВАРИАНТЫ), СПОСОБ ИХ ПОЛУЧЕНИЯ (ВАРИАНТЫ), КОМПОЗИЦИЯ НА ИХ ОСНОВЕ, СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С МОДУЛЯЦИЕЙ РЕЦЕПТОРОВ GABAA, ИЛИ α1-GABAA, ИЛИ α2-GABAA (ВАРИАНТЫ)
|
|
WO2006070806A1
(ja)
|
2004-12-28 |
2006-07-06 |
Taiho Pharmaceutical Co., Ltd. |
新規ベンゾイミダゾール化合物及び該化合物を含有する医薬組成物
|
|
WO2006119435A2
(en)
|
2005-05-04 |
2006-11-09 |
Invitrogen Corporation |
Identification of cancer biomarkers and phosphorylated proteins
|
|
AU2007288124B2
(en)
|
2006-08-24 |
2013-04-04 |
Australian Nuclear Science & Technology Organisation |
Fluorinated ligands for targeting peripheral benzodiazepine receptors
|
|
US8324367B2
(en)
|
2006-11-03 |
2012-12-04 |
Medtronic, Inc. |
Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
|
|
CA2688194A1
(en)
*
|
2007-05-23 |
2008-12-04 |
Siga Technologies, Inc. |
Antiviral drugs for treatment or prevention of dengue infection
|
|
WO2008157500A1
(en)
|
2007-06-17 |
2008-12-24 |
Kalypsys, Inc. |
Aminoquinazoline cannabinoid receptor modulators for treatment of disease
|
|
WO2009086303A2
(en)
|
2007-12-21 |
2009-07-09 |
University Of Rochester |
Method for altering the lifespan of eukaryotic organisms
|
|
CA2618163A1
(en)
|
2008-02-07 |
2009-08-07 |
K. W. Michael Siu |
Head and neck cancer biomarkers
|
|
CA2716947A1
(en)
|
2008-02-29 |
2009-09-11 |
Array Biopharma Inc. |
Imidazo [4,5-b] pyridine derivatives used as raf inhibitors
|
|
EP2349484A2
(en)
|
2008-07-15 |
2011-08-03 |
Novartis AG |
Heteroaryl derivatives as dgat1 inhibitors
|
|
KR20110128283A
(ko)
|
2009-02-05 |
2011-11-29 |
타겟티드 딜리버리 테크놀러지스 리미티드 |
미생물체의 증식 및 생존도를 감소시키는 방법
|
|
KR101609856B1
(ko)
|
2010-03-17 |
2016-04-07 |
타이벡스 세라피틱스 코포레이션 |
Ｈｅｃ１ 활성의 조절인자 및 이의 방법
|
|
BR112012027104B8
(pt)
|
2010-04-22 |
2020-02-27 |
British Columbia Cancer Agency Branch |
método de acordo para determinar se a endometriose de um individuo é suscetível de progredir para carcinoma de células claras ovariano , carcinoma endometrioide, carcinoma endometrial e carcinoma uterino, para determinar a prognose para uma pessoa sofrendo de carcinoma de células claras ovariano, e/ou para determinar se agentes quimioterapêuticos padrões são prováveis de serem efetivos no tratamento de carcinoma de células claras ovariano, carcinoma endometrioide, carcinoma endometrial e carcinoma uterino
|
|
US20120035244A1
(en)
|
2010-07-29 |
2012-02-09 |
The Regents Of The University Of Michigan |
Parp1 targeted therapy
|
|
US9072052B2
(en)
|
2010-08-09 |
2015-06-30 |
Blackberry Limited |
Communication system providing context-based mobile wireless communications device power consumption management and related methods
|
|
EP2655330B1
(en)
|
2010-12-22 |
2016-02-10 |
Purdue Pharma LP |
Substituted pyridines as sodium channel blockers
|
|
EP2694678A2
(en)
|
2011-04-04 |
2014-02-12 |
Netherland Cancer Institute |
Methods and compositions for predicting resistance to anticancer treatment
|
|
ES2733211T3
(es)
|
2011-04-15 |
2019-11-28 |
Genelux Corp |
Cepas clonales de virus vaccinia atenuados y métodos de uso de las mismas
|
|
US8945861B2
(en)
|
2011-08-03 |
2015-02-03 |
Pierce Biotechnology, Inc. |
Methods for isotopically labeling biomolecules using mammalian cell-free extracts
|
|
JP6175078B2
(ja)
|
2012-02-01 |
2017-08-02 |
ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク |
新規のシステインプロテアーゼ阻害剤及びその使用
|
|
EP2809660B1
(en)
|
2012-02-02 |
2016-01-20 |
Ensemble Therapeutics Corporation |
Macrocyclic compounds for modulating il-17
|
|
AU2013266968B2
(en)
|
2012-05-25 |
2017-06-29 |
Emmanuelle CHARPENTIER |
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
|
|
CN113355357B
(zh)
|
2012-12-12 |
2024-12-03 |
布罗德研究所有限公司 |
对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
EP2840140B2
(en)
|
2012-12-12 |
2023-02-22 |
The Broad Institute, Inc. |
Crispr-Cas based method for mutation of prokaryotic cells
|
|
US9410943B2
(en)
|
2013-03-14 |
2016-08-09 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods, compositions and screens for therapeutics for the treatment of synovial sarcoma
|
|
CN105473141A
(zh)
|
2013-03-15 |
2016-04-06 |
实发生物医学公司 |
治疗和/或预防心血管疾病的抗pcsk9化合物和方法
|
|
WO2014150751A2
(en)
|
2013-03-15 |
2014-09-25 |
Novartis Ag |
Biomarkers associated with brm inhibition
|
|
US10976320B2
(en)
|
2013-05-21 |
2021-04-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for identifying and treating cancer patients
|
|
EP3018123B1
(en)
|
2013-07-03 |
2023-05-10 |
Takeda Pharmaceutical Company Limited |
Amide compound
|
|
JPWO2015005473A1
(ja)
|
2013-07-12 |
2017-03-02 |
国立研究開発法人国立がん研究センター |
がんの治療への応答性を予測する方法
|
|
EP3022197B1
(en)
|
2013-07-15 |
2017-09-06 |
Boehringer Ingelheim International GmbH |
Novel tetra- and pentasubstituted benzimidazolium compounds
|
|
WO2015046193A1
(ja)
|
2013-09-25 |
2015-04-02 |
塩野義製薬株式会社 |
Ｔｒｐｖ４阻害活性を有する芳香族複素環式アミン誘導体
|
|
CA2935683A1
(en)
|
2013-12-30 |
2015-07-09 |
Lifesci Pharmaceuticals, Inc. |
Therapeutic inhibitory compounds
|
|
WO2015120320A1
(en)
|
2014-02-06 |
2015-08-13 |
Rutgers, The State University Of New Jersey |
Antibacterial agents: n(alpha)-aroyl-n-aryl-phenylalaninamides
|
|
GB201402771D0
(en)
|
2014-02-17 |
2014-04-02 |
Isis Innovation |
Biomarker & therapeutic target for sarcoma
|
|
PT3177640T
(pt)
|
2014-08-08 |
2020-08-31 |
Univ Leland Stanford Junior |
Agentes pd-1 de alta afinidade e métodos de utilização
|
|
WO2016054491A1
(en)
|
2014-10-03 |
2016-04-07 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
US9636323B2
(en)
|
2014-10-27 |
2017-05-02 |
Baylor College Of Medicine |
Method of treating cancer that overexpresses TopBP1
|
|
CN104530013B
(zh)
|
2014-12-04 |
2016-06-29 |
中国农业大学 |
基于吲哚环的吡唑酰胺类化合物作为农用杀菌剂的用途
|
|
US9546296B2
(en)
|
2014-12-15 |
2017-01-17 |
Ppg Industries Ohio, Inc. |
Coating compositions, coatings and methods for sound and vibration damping and water resistance
|
|
US9932340B2
(en)
|
2014-12-18 |
2018-04-03 |
Abbvie Inc. |
Substituted indoles
|
|
WO2016105518A1
(en)
|
2014-12-23 |
2016-06-30 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
US9694084B2
(en)
|
2014-12-23 |
2017-07-04 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
MA41598A
(fr)
|
2015-02-25 |
2018-01-02 |
Constellation Pharmaceuticals Inc |
Composés thérapeutiques de pyridazine et leurs utilisations
|
|
WO2016160718A1
(en)
|
2015-03-27 |
2016-10-06 |
University Of Washington |
Methods for treatment of retinal disease by photoreceptor gene expression modulation
|
|
US20180140722A1
(en)
|
2015-04-06 |
2018-05-24 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for treatment of heart failure
|
|
EP3108883A1
(en)
|
2015-06-22 |
2016-12-28 |
Fundació Institut de Recerca Biomèdica de Bellvitge |
Therapeutic uses of non-peptide inhibitors of the calcineurin - nfat signalling pathway
|
|
WO2017007612A1
(en)
|
2015-07-07 |
2017-01-12 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
WO2017024318A1
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
|
|
US20170100396A1
(en)
|
2015-10-07 |
2017-04-13 |
F. Hoffmann-La Roche Ag |
Pyrrolopyrazine derivatives for use in the treatment, amelioration or prevention of influenza
|
|
FI3362065T3
(fi)
|
2015-10-15 |
2024-06-19 |
Servier Lab |
Ivosidenibiä, sytarabiinia ja daunorubisiinia tai idarubisiinia käsittävä yhdistelmähoito akuutin myelooisen leukemian hoitamiseksi
|
|
WO2017087885A1
(en)
|
2015-11-19 |
2017-05-26 |
Dana-Farber Cancer Institute, Inc. |
Methods of identifying compounds that interfere with erg-driven misguidance of baf complexes in tmprss2-erg driven prostate cancers
|
|
WO2017118734A1
(en)
|
2016-01-08 |
2017-07-13 |
The Institute Of Cancer Research: Royal Cancer Hospital |
Inhibitors of ataxia-telangiectasia mutated and rad3-related protein kinase (atr) for use in methods of treating cancer
|
|
MA43640A
(fr)
|
2016-02-26 |
2018-11-28 |
Agios Pharmaceuticals Inc |
Inhibiteurs de idh1 pour le traitement de cancers hématologiques et de tumeurs solides
|
|
CN113336029B
(zh)
|
2016-02-29 |
2022-12-20 |
富士达株式会社 |
电梯系统
|
|
GB201604638D0
(en)
|
2016-03-18 |
2016-05-04 |
Mission Therapeutics Ltd |
Novel compounds
|
|
EP3454856B1
(en)
|
2016-05-10 |
2024-09-11 |
C4 Therapeutics, Inc. |
Heterocyclic degronimers for target protein degradation
|
|
CN109641874A
(zh)
|
2016-05-10 |
2019-04-16 |
C4医药公司 |
用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
|
|
ES2990061T3
(es)
|
2016-05-10 |
2024-11-28 |
C4 Therapeutics Inc |
Degronímeros espirocíclicos para la degradación de proteínas diana
|
|
WO2018064589A1
(en)
|
2016-09-29 |
2018-04-05 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation using a mutant e3 ubiquitin ligase
|
|
US10207998B2
(en)
|
2016-09-29 |
2019-02-19 |
Duke University |
Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
|
|
AU2018219292B2
(en)
|
2017-02-08 |
2024-09-26 |
Dana-Farber Cancer Institute, Inc. |
Tunable endogenous protein degradation with heterobifunctional compounds
|
|
CN110366418A
(zh)
|
2017-02-28 |
2019-10-22 |
埃皮兹姆公司 |
抑制smarca2用于治疗癌症
|
|
US11555031B2
(en)
|
2017-03-20 |
2023-01-17 |
The Broad Institute, Inc. |
Compounds and methods for regulating insulin secretion
|
|
TWI791593B
(zh)
|
2017-08-21 |
2023-02-11 |
德商馬克專利公司 |
做為腺苷受體拮抗劑之苯并咪唑衍生物
|
|
US20200206344A1
(en)
|
2017-08-21 |
2020-07-02 |
Dana-Farber Cancer Institute, Inc. |
Methods for modulating the interaction between ews-fli1 and baf complexes
|
|
US11472794B2
(en)
|
2018-01-15 |
2022-10-18 |
UCB Biopharma SRL |
Fused imidazole derivatives as IL-17 modulators
|
|
EP3740482A1
(en)
|
2018-01-17 |
2020-11-25 |
Migal Galilee Research Institute Ltd. |
New methionine metabolic pathway inhibitors
|
|
US11497752B2
(en)
|
2018-01-30 |
2022-11-15 |
Foghorn Therapeutics Inc. |
Compounds and uses thereof
|
|
EP3746135A4
(en)
|
2018-01-30 |
2022-03-09 |
Foghorn Therapeutics Inc. |
METHODS AND COMPOUNDS FOR TREATMENT OF DISEASE
|
|
US11447502B2
(en)
|
2018-05-25 |
2022-09-20 |
Rutgers, The State University Of New Jersey |
Antibacterial agents: dual-targeted RNA polymerase inhibitors
|
|
US20210251988A1
(en)
|
2018-06-21 |
2021-08-19 |
Foghorn Therapeutics Inc. |
Methods of treating disorders
|
|
WO2019246423A1
(en)
|
2018-06-21 |
2019-12-26 |
Foghorn Therapeutics Inc. |
Methods of treating disorders
|
|
PT3837256T
(pt)
|
2018-08-17 |
2023-05-23 |
Novartis Ag |
Compostos e composições de ureia como inibidores de smarca2/brm-atpase
|
|
US20210171958A1
(en)
|
2018-08-23 |
2021-06-10 |
Foghorn Therapeutics Inc. |
Methods of treating cancer
|
|
WO2020081556A2
(en)
|
2018-10-17 |
2020-04-23 |
Dana-Farber Cancer Institute, Inc. |
Non-canonical swi/snf complex and uses thereof
|
|
WO2020081588A1
(en)
|
2018-10-17 |
2020-04-23 |
Dana-Farber Cancer Institute, Inc. |
Swi/snf family chromatin remodeling complexes and uses thereof
|
|
JP2022508155A
(ja)
|
2018-11-21 |
2022-01-19 |
フォグホーン セラピューティクス インコーポレイテッド |
がんを治療する方法
|
|
SG11202106444WA
(en)
|
2018-12-19 |
2021-07-29 |
Leo Pharma As |
Amino-acid anilides as small molecule modulators of il-17
|
|
CN113645971B
(zh)
|
2019-01-29 |
2024-10-18 |
福宏治疗公司 |
化合物及其用途
|
|
US12384776B2
(en)
|
2019-01-29 |
2025-08-12 |
Foghorn Therapeutics Inc. |
Compounds and uses thereof
|
|
US12509453B2
(en)
|
2019-01-29 |
2025-12-30 |
Foghorn Therapeutics Inc. |
BRM/BRG1 inhibitors and uses thereof
|
|
WO2020191326A1
(en)
|
2019-03-20 |
2020-09-24 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (aml) with venetoclax failure
|
|
PH12022550578A1
(en)
|
2019-09-12 |
2024-02-19 |
Aurigene Discovery Tech Ltd |
Method for identifying responders to smarca2/4 degraders
|
|
US20220396604A1
(en)
|
2019-10-25 |
2022-12-15 |
Dana-Farber Cancer Institute, Inc. |
Compositions comprising modified smarcb1 and uses thereof
|
|
EA202192101A1
(ru)
|
2019-11-21 |
2021-12-09 |
Фогхорн Терапьютикс Инк. |
Соединения и их применение
|
|
EP4096667A4
(en)
|
2020-01-29 |
2024-03-06 |
Foghorn Therapeutics Inc. |
COMPOUNDS AND USES THEREOF
|
|
AU2021213811A1
(en)
|
2020-01-29 |
2022-07-28 |
Foghorn Therapeutics Inc. |
Compounds and uses thereof
|
|
JP7693688B2
(ja)
|
2020-01-29 |
2025-06-17 |
フォグホーン セラピューティクス インコーポレイテッド |
化合物およびその使用
|
|
EP4096651A4
(en)
|
2020-01-29 |
2024-01-24 |
Foghorn Therapeutics Inc. |
COMPOUNDS AND THEIR USES
|
|
CN115484948A
(zh)
|
2020-01-29 |
2022-12-16 |
福宏治疗公司 |
化合物及其用途
|
|
WO2021155264A1
(en)
|
2020-01-29 |
2021-08-05 |
Foghorn Therapeutics Inc. |
Compounds and uses thereof
|
|
US20250283871A1
(en)
|
2020-03-13 |
2025-09-11 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating the interaction between ss18-ssx fusion oncoprotein and nucleosomes
|
|
US12383555B2
(en)
|
2020-05-20 |
2025-08-12 |
Foghorn Therapeutics Inc. |
Methods of treating cancers
|
|
EP4153176A4
(en)
|
2020-05-20 |
2024-05-29 |
Foghorn Therapeutics Inc. |
METHODS OF TREATING CANCER
|
|
US12606553B2
(en)
|
2021-03-09 |
2026-04-21 |
Foghorn Therapeutics Inc. |
Crystalline forms, compositions containing same, and methods of their use
|
|
WO2022192621A1
(en)
|
2021-03-12 |
2022-09-15 |
Celgene Corporation |
Methods for using a hypomethylating agent to treat diseases and disorders based on gene mutation profiles
|
|
CN117337179A
(zh)
|
2021-03-19 |
2024-01-02 |
福宏治疗公司 |
Brg1和brm的酶活性抑制剂的治疗方案
|
|
US20240374605A1
(en)
|
2021-07-29 |
2024-11-14 |
Foghorn Therapeutics Inc. |
Methods of treating cancer
|
|
CN119343142A
(zh)
|
2022-04-08 |
2025-01-21 |
福宏治疗公司 |
治疗具有与血细胞分化相关的临床显著体征和症状的受试者的方法
|
|
US20250325553A1
(en)
|
2022-04-08 |
2025-10-23 |
Foghorn Therapeutics Inc. |
Methods of treating cancer
|
|
US20250339441A1
(en)
|
2022-04-08 |
2025-11-06 |
Foghorn Therapeutics Inc. |
Methods of treating cancer
|
|
CN218451564U
(zh)
|
2022-08-09 |
2023-02-07 |
宁波立奇电器有限公司 |
一种双锅双风道式空气炸锅
|
|
WO2024086577A1
(en)
|
2022-10-17 |
2024-04-25 |
Foghorn Therapeutics Inc. |
Methods of reducing or preventing metastases
|
|
WO2024216136A1
(en)
|
2023-04-13 |
2024-10-17 |
Foghorn Therapeutics Inc. |
Combination therapy for the treatment of hematological cancers
|
|
WO2024216151A1
(en)
|
2023-04-13 |
2024-10-17 |
Foghorn Therapeutics Inc. |
Combination therapy for treating hematological cancers
|
|
WO2024249769A2
(en)
|
2023-06-02 |
2024-12-05 |
Foghorn Therapeutics Inc. |
Combination therapy for treating hematological cancers
|
|
WO2025080769A1
(en)
|
2023-10-10 |
2025-04-17 |
Foghorn Therapeutics Inc. |
Methods of treating cancer
|
|
WO2025080767A1
(en)
|
2023-10-10 |
2025-04-17 |
Foghorn Therapeutics Inc. |
Differentiation and maintenance dosing regimen for fhd 286 (brg1/brm inhibitor)
|